Abstract: Provided is a pharmaceutical formulation comprising 10-80 mg/ml of bevacizumab. The buffer system of the pharmaceutical formulation is preferably 10-30 mM histidine hydrochloride-sodium acetate buffer, in which 25-50 mg/mL of sucrose or sorbitol is used as a stabilizer, and Tween 80 is used as a surfactant, and the system has a pH of 5.0-5.6. The formulation is tested under repeated freezing and thawing and high-temperature acceleration conditions of 40° C. The protein stability is good, and is better than other similar formulations.

Abstract: A test socket assembly includes a contactor body having one or more compliant interconnects, and a socket opening sized and configured to receive a device under test therein. The test socket assembly further includes a lead frame assembly disposed within the contactor body and electrically coupled with the one or more compliant interconnects, and one or more antennas at least partially disposed within the contactor body, the one or more antennas configured to directly and wirelessly communicate to the device under test when the device is disposed within the socket opening.

Abstract: The present invention provides a pharmaceutical formulation containing an anti-PD-1 monoclonal antibody. The pharmaceutical formulation comprises an anti-PD-1 monoclonal antibody, a citrate-sodium citrate buffer solution, a protein protectant, a surfactant, and an isotonic regulator. The present invention also relates to an application of the pharmaceutical formulation in the preparation of a liquid formulation or lyophilized formulation for injection.

Abstract: A test socket assembly including a contactor body having a socket opening sized and configured to receive a device under test therein, and one or more waveguides at least partially disposed within the contactor body or external to the contactor body. The assembly further including at least one waveguide antenna probe coupled with the one or more waveguides, where the at least one waveguide antenna probe including a first set of sides and a second set of sides, at least one of the first set of sides are flared out away from the longitudinal axis.

Abstract: A test socket assembly includes a contactor body having one or more compliant interconnects, and a socket opening sized and configured to receive a device under test therein. The test socket assembly further includes a lead frame assembly disposed within the contactor body and electrically coupled with the one or more compliant interconnects, and one or more antennas at least partially disposed within the contactor body, the one or more antennas configured to directly and wirelessly communicate to the device under test when the device is disposed within the socket opening.

Abstract: A test socket assembly including a contactor body having a socket opening sized and configured to receive a device under test therein, and one or more waveguides at least partially disposed within the contactor body or external to the contactor body. The assembly further including at least one waveguide antenna probe coupled with the one or more waveguides, where the at least one waveguide antenna probe including a first set of sides and a second set of sides, at least one of the first set of sides are flared out away from the longitudinal axis.

Abstract: An antenna (10) is provided including a generally rectangular ground element (20) having a first end and a second end. The ground element (20) includes at least one hole (30, 30?) for mounting the antenna to a support structure. A generally rectangular radiating element (12) having a third end and a fourth end if parallel to the ground element (20) and separated from the ground element (20) by a space. A bend connects the first end of the ground element (20) to the third end of the radiating element (12). A coaxial cable includes a center conductor coupled to the radiating element (12) at a feed point and an outer conductor coupled to the ground element (20). The coaxial cable acts as a feed line that couples the antenna (10) to an external transmitter or receiver.

Abstract: An antenna (10) is provided including a generally rectangular ground element (20) having a first end and a second end. The ground element (20) includes at least one hole (30, 30?) for mounting the antenna to a support structure. A generally rectangular radiating element (12) having a third end and a fourth end if parallel to the ground element (20) and separated from the ground element (20) by a space. A bend connects the first end of the ground element (20) to the third end of the radiating element (12). A coaxial cable includes a center conductor coupled to the radiating element (12) at a feed point and an outer conductor coupled to the ground element (20). The coaxial cable acts as a feed line that couples the antenna (10) to an external transmitter or receiver.

Abstract: Described herein is the creation and use of Thermotoga-E. coli shuttle vectors; an embedded cultivation method that greatly simplifies the cultivation methods for Thermotoga previously used; and the subcloning, characterization, and use of a Thermotoga Restriction-modification system.

Abstract: We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells.

Abstract: We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells.

Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.

Abstract: The present invention relates to compounds and methods use as inhibitors of c-Met. Certain compounds of the subject invention have the following structural formula (I). Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

Abstract: The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognition. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.

Abstract: The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.

Abstract: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

Abstract: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

Abstract: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

Abstract: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

Abstract: In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.